Predictive Factors of Early Super-Response to Biologic Agents in Psoriasis: Insights from Real-World Evidence

银屑病生物制剂早期超敏反应的预测因素:来自真实世界证据的启示

阅读:1

Abstract

BACKGROUND/OBJECTIVES: The concept of early super-response (ESR) in psoriasis, characterized by rapid and sustained complete skin clearance, has recently gained clinical relevance. However, evidence regarding predictors of ESR remains limited. This study aimed to identify clinical and laboratory factors associated with ESR in patients with psoriasis vulgaris treated with biologics. METHODS: In this retrospective study, 299 patients with psoriasis vulgaris receiving biologic therapy were evaluated. ESR was defined as achieving a PASI 100 response at week 4 and maintaining PASI < 1 through week 48. Demographic, clinical, and laboratory parameters were compared between ESR and non-ESR groups. Variables with p < 0.1 in univariate analyses were entered into multivariate logistic regression to identify independent predictors. RESULTS: Bio-naïve status (OR = 2.16, 95% CI 1.17-3.96, p = 0.013) and higher baseline neutrophil count (OR = 1.26, 95% CI 1.04-1.53, p = 0.016) were independent positive predictors of ESR, while palmoplantar involvement (OR = 0.27, 95% CI 0.13-0.58, p = 0.001) was a strong negative predictor. Smoking (OR = 0.57, 95% CI 0.29-1.11, p = 0.099) showed a borderline negative association, and platelet-to-lymphocyte ratio (PLR) (OR = 1.005, 95% CI 0.999-1.01, p = 0.083) demonstrated a borderline positive effect. At the biologic class level, no statistically significant differences in ESR rates were observed. Moreover, biologic class was not independently associated with ESR in multivariable analyses after adjustment for clinically relevant covariates. CONCLUSION: Bio-naïve status and elevated baseline neutrophil count predicted rapid and sustained complete clearance with biologic therapy, whereas palmoplantar involvement impaired early response. These findings emphasize the prognostic role of baseline inflammatory and phenotypic features in guiding personalized psoriasis management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。